AAA
IOVA icon

Affinity Asset Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Affinity Asset Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100
Closed -$802 – 95
2024
Q2 		$802 Buy
+100
New +$1.07K ﹤0.01% 98
2023
Q1 		– Sell
-375,000
Closed -$2.4M – 81
2022
Q4 		$2.4M Buy
+375,000
New +$2.93M 0.94% 33
2022
Q1 		– Sell
-20,000
Closed -$382K – 67
2021
Q4 		$382K Sell
20,000
-130,000
-87% -$2.86M 0.14% 53
2021
Q3 		$3.7M Buy
150,000
+50,000
+50% +$1.18M 0.93% 26
2021
Q2 		$2.6M Buy
100,000
+75,400
+307% +$1.96M 0.93% 28
2021
Q1 		$779K Buy
24,600
+5,000
+26% +$207K 0.26% 55
2020
Q4 		$909K Buy
+19,600
New +$778K 0.48% 43

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Affinity Asset Advisors's IOVA Position: Q3 2024 in Review

Affinity Asset Advisors sold out of Iovance Biotherapeutics (IOVA) in Q3 2024, closing a stake of 100 shares — an estimated $802 sold.

Affinity Asset Advisors first reported a position in IOVA in Q4 2020 and held it in 7 quarters. The position peaked at $3.7M in Q3 2021. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

  • Affinity Asset Advisors reported no remaining Iovance Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Affinity Asset Advisors sold 100 Iovance Biotherapeutics shares in Q3 2024, an estimated $802.
  • Affinity Asset Advisors first reported a position in Iovance Biotherapeutics in Q4 2020 and held it in 7 quarters.
  • Affinity Asset Advisors's Iovance Biotherapeutics position peaked at $3.7M in Q3 2021.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on Affinity Asset Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.